Since inhibition of ETC complex II activity in FLT3-ITD+ AML resulted in an increasing shift towards lactate-driven OCR we wished to exploit this therapeutically by inhibiting both ETC complex II (using 3-NPA or TTFA) and MCT1 transporters to prevent lactate import (Fig. 5a). Here, FLT3 is linked to acute myeloid leukemia.